THERAPY DOSSIER · th-b59edbb5dc11

Plant-derived human recombinant type I collagen flowable gel

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23259631 ↗2013Reported benefit

Cutaneous wound healing after treatment with plant-derived human recombinant collagen flowable gel.

RatWoundTopical application to the wound

Model: Acute full-thickness cutaneous wound

The recombinant collagen gel accelerated wound closure and re-epithelialisation compared with saline and two commercial collagen gels in rats, and in the pig model produced 95% wound closure by day 21 compared with 68% for the reference bovine tendon collagen product, with an earlier angiogenic res…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…